In the December 2023 issue of this magazine, Markus Meyer looked at how early and accurate identification can assist in controlling outbreaks of Candida auris, thanks to advances in polymerase chain reaction testing and strain typing technology. Here, to complement previous coverage, Pathology in Practice Science Editor Brian Nation compiles a small selection of recent research interest in this important fungal agent.
Candida auris: the new fungal threat
Pallotta F, Viale P, Barchiesi F. Infez Med. 2023 Sep 1; 31 (3): 323–8. doi: 10.53854/liim-3103-6. eCollection 2023.
Candida auris is an emergent fungal pathogen of particular concern. Since its first identification in Japan in 2009, it rapidly spread all over the world, including Italy. The main concern related to the diffusion of this fungus is its antifungal resistance. It is speculated that about 90% of isolates are resistant to fluconazole, 30% to amphotericin B and 5% to echinocandins; furthermore, some cases of pan-antifungal resistance have been described.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.